Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OMEROS CORPORATION

(OMER)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Omeros : Says OMS906 Was Well-Tolerated in Phase 1 Trial in Alternative Pathway-Related Disorders

06/09/2021 | 10:27am EDT


ę MT Newswires 2021
All news about OMEROS CORPORATION
08/09OMEROS : Q2 Loss Narrows on Rising Revenue -- Stock Up 3% After-Hours
MT
08/09OMEROS : Q2 Earnings Snapshot
AQ
08/09OMEROS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERAT..
AQ
08/09OMEROS CORP : Results of Operations and Financial Condition, Financial Statements and Exhi..
AQ
08/09OMEROS CORPORATION : Reports Second Quarter 2021 Financial Results
BU
08/09Omeros Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
08/03OMEROS CORPORATION : to Announce Second Quarter Financial Results on August 9, 2021
BU
06/18OMEROS : WBB Securities Reinstates Omeros With Strong Buy, $100 Price Target
MT
06/16OMEROS : Form 8-K)
PU
06/16OMEROS CORP : Submission of Matters to a Vote of Security Holders, Financial Statements an..
AQ
More news
Analyst Recommendations on OMEROS CORPORATION
More recommendations
Financials (USD)
Sales 2021 112 M - -
Net income 2021 -122 M - -
Net Debt 2021 258 M - -
P/E ratio 2021 -8,32x
Yield 2021 -
Capitalization 997 M 997 M -
EV / Sales 2021 11,2x
EV / Sales 2022 6,77x
Nbr of Employees 277
Free-Float 95,9%
Chart OMEROS CORPORATION
Duration : Period :
Omeros Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OMEROS CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 15,95 $
Average target price 27,00 $
Spread / Average Target 69,3%
EPS Revisions
Managers and Directors
Gregory A. Demopulos Chairman, President & Chief Executive Officer
Michael A. Jacobsen Chief Financial Officer, Treasurer & VP
George A. Gaitanaris Chief Scientific Officer & Vice President-Science
J. Steven Whitaker Chief Medical Officer & Vice President
Ray Aspiri Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OMEROS CORPORATION11.66%997
GILEAD SCIENCES, INC.23.05%89 497
BIONTECH SE333.01%81 938
WUXI APPTEC CO., LTD.33.88%69 841
REGENERON PHARMACEUTICALS33.82%67 273
VERTEX PHARMACEUTICALS-21.68%47 805